Astrazeneca's Trixeo Aerosphere secures EU approval
By Iain Gilbert
Date: Wednesday 23 Sep 2026
(Sharecast News) - Drugmaker Astrazeneca said on Wednesday that its Trixeo Aerosphere candidate has been approved in the European Union as a maintenance treatment for asthma in patients aged 12 and over.
Astrazeneca stated Trixeo was now the first and only triple‑combination therapy cleared in the EU for this age group, regardless of exacerbation history, with the single‑inhaler treatment combining an inhaled corticosteroid, a long‑acting beta2‑agonist and a long‑acting muscarinic antagonist. The drug was already marketed as Breztri Aerosphere in the US, China and Japan.
The European Commission's decision followed a positive opinion from the EMA's CHMP and was supported by results from its Phase III KALOS and LOGOS trials.
Astrazeneca said Trixeo delivered statistically significant improvements in lung function versus dual ICS/LABA comparators. In pooled analyses, it also reduced the annualised rate of severe asthma exacerbations across a broad patient population, including those without exacerbations in the prior year.
As of 1100 BST, Astrazeneca shares were down 0.96% at 12,550p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS at Investegate
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN